ATE355385T1 - Herstellung von rekombinanten adenoviren und von adenovirus-genbanken - Google Patents

Herstellung von rekombinanten adenoviren und von adenovirus-genbanken

Info

Publication number
ATE355385T1
ATE355385T1 AT00967960T AT00967960T ATE355385T1 AT E355385 T1 ATE355385 T1 AT E355385T1 AT 00967960 T AT00967960 T AT 00967960T AT 00967960 T AT00967960 T AT 00967960T AT E355385 T1 ATE355385 T1 AT E355385T1
Authority
AT
Austria
Prior art keywords
preparation
recombinant adenoviruses
adenoviruses
adenovirus gene
banks
Prior art date
Application number
AT00967960T
Other languages
English (en)
Inventor
Jean-Jacques Robert
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of ATE355385T1 publication Critical patent/ATE355385T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
AT00967960T 1999-10-07 2000-10-05 Herstellung von rekombinanten adenoviren und von adenovirus-genbanken ATE355385T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9912521A FR2799472B1 (fr) 1999-10-07 1999-10-07 Preparation d'adenovirus recombinants et de banques adenovirales
US16835699P 1999-12-01 1999-12-01

Publications (1)

Publication Number Publication Date
ATE355385T1 true ATE355385T1 (de) 2006-03-15

Family

ID=26235132

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00967960T ATE355385T1 (de) 1999-10-07 2000-10-05 Herstellung von rekombinanten adenoviren und von adenovirus-genbanken

Country Status (22)

Country Link
US (1) US8263395B2 (de)
EP (1) EP1224310B1 (de)
JP (1) JP5260815B2 (de)
KR (1) KR100928105B1 (de)
CN (1) CN1384885B (de)
AT (1) ATE355385T1 (de)
AU (1) AU785431B2 (de)
BR (1) BR0014489B1 (de)
CA (1) CA2383225C (de)
CZ (1) CZ302282B6 (de)
DE (1) DE60033679T2 (de)
DK (1) DK1224310T3 (de)
FR (1) FR2799472B1 (de)
HK (1) HK1050211B (de)
HU (1) HU228933B1 (de)
IL (2) IL148493A0 (de)
MX (1) MXPA02003247A (de)
NO (1) NO330916B1 (de)
NZ (1) NZ518763A (de)
PL (1) PL210590B1 (de)
WO (1) WO2001025463A1 (de)
ZA (1) ZA200202481B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1254212A2 (de) 2000-02-09 2002-11-06 Genvec, Inc. Verfahren zur herstellung und verwendung von einer bibliothek von viralen vektoren
EP2471909A1 (de) * 2010-12-30 2012-07-04 SIRION BIOTECH GmbH Nukleinsäuremoleküle zur Herstellung adenoviraler Vektoren
GB201322851D0 (en) * 2013-12-23 2014-02-12 Psioxus Therapeutics Ltd Method
CN109576231B (zh) * 2017-09-28 2022-03-25 北京康万达医药科技有限公司 分离的重组溶瘤腺病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途
US11845952B2 (en) 2018-02-07 2023-12-19 Nippon Medical School Foundation Adeno-associated virus vector

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0140308B2 (de) 1983-10-20 2001-10-17 The Research Foundation Of State University Of New York Regulierung von Gen-Expression durch Translationshemmung unter Verwendung von m-RNS hinderndem Komplementär-RNS
FR2573436B1 (fr) 1984-11-20 1989-02-17 Pasteur Institut Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins
US6696420B1 (en) * 1984-11-20 2004-02-24 Institut Pasteur Adenoviral vector with a deletion in the E1A coding region expressing a hetorologous protein
FR2602790B1 (fr) 1986-08-13 1990-06-01 Transgene Sa Expression d'un antigene specifique de tumeur par un virus vecteur recombinant et utilisation de celui-ci pour le traitement preventif ou curatif de la tumeur correspondante
US5744133A (en) * 1986-08-13 1998-04-28 Transgene S.A. Expression of a tumor-specific antigen by a recombinant vector virus and use thereof in preventitive or curative treatment of the corresponding tumor
US6007806A (en) * 1986-08-13 1999-12-28 Transgene S.A. Expression of a tumor-specific antigen by a recombinant vector virus and use thereof in preventive or curative treatment of the corresponding tumor
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
AU680459B2 (en) 1992-12-03 1997-07-31 Genzyme Corporation Gene therapy for cystic fibrosis
FR2704556B1 (fr) 1993-04-30 1995-07-13 Rhone Poulenc Rorer Sa Virus recombinants et leur utilisation en thérapie génique.
FR2705363B1 (fr) 1993-05-13 1995-08-11 Clecim Sa Procédé de fusion de ferraille dans un four électrique et installation pour la mise en Óoeuvre du procédé.
FR2705361B1 (fr) 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
US6133028A (en) * 1993-05-28 2000-10-17 Transgene S.A. Defective adenoviruses and corresponding complementation lines
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
NZ269156A (en) 1993-07-13 1996-03-26 Rhone Poulenc Rorer Sa Defective recombinant adenovirus vector incapable of replicating autonomously in a target cell and its use in gene therapy
FR2718150B1 (fr) * 1994-03-29 1996-04-26 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
ATE336587T1 (de) 1994-06-10 2006-09-15 Genvec Inc Adenoviren-vektor systeme und zelllinien
FR2724945B1 (fr) 1994-09-27 1996-12-27 Centre Nat Rech Scient Vecteurs viraux et utilisation en therapie genique
FR2726285B1 (fr) 1994-10-28 1996-11-29 Centre Nat Rech Scient Adenovirus depourvus de particules contaminantes viables, preparation et utilisation
FR2730504B1 (fr) * 1995-02-13 1997-03-28 Rhone Poulenc Rorer Sa Procede de preparation de genomes d'adenovirus recombinants
FR2730411B1 (fr) * 1995-02-14 1997-03-28 Centre Nat Rech Scient Association medicamenteuse utile pour la transfection et l'expression in vivo d'exogenes
JP4020429B2 (ja) * 1995-06-07 2007-12-12 インヴィトロジェン コーポレーション 操作された組換え部位を使用する組換えクローニング
US5783431A (en) * 1996-04-24 1998-07-21 Chromaxome Corporation Methods for generating and screening novel metabolic pathways
FR2749857B1 (fr) 1996-06-12 1998-08-14 Centre Nat Rech Scient Generation de molecules replicatives in vivo
FR2755975B1 (fr) * 1996-11-15 1999-05-07 Rhone Poulenc Rorer Sa Virus recombinants bicistroniques utiles pour le traitement de pathologies liees aux dyslipoproteinemies
US5846812A (en) * 1996-11-22 1998-12-08 Pioneer Hi-Bred International, Inc. Zearalenone detoxification compositions and methods
FR2774699B1 (fr) * 1997-11-17 2003-10-03 Rhone Poulenc Rorer Sa Methode de reduction des evenements de recombinaison homologue
US5922576A (en) * 1998-02-27 1999-07-13 The John Hopkins University Simplified system for generating recombinant adenoviruses
US6844270B2 (en) * 2000-11-26 2005-01-18 Shipley Company, L.L.C. Polymers and photoresist compositions for short wavelength imaging
SE523617C2 (sv) * 2001-10-01 2004-05-04 Sandvik Ab Skär för spånavskiljande bearbetning försedd med spånbrytande geometri
JP4308485B2 (ja) * 2002-07-08 2009-08-05 パナソニック株式会社 容量素子の製造方法
US6856551B2 (en) * 2003-02-06 2005-02-15 Sandisk Corporation System and method for programming cells in non-volatile integrated memory devices

Also Published As

Publication number Publication date
CN1384885A (zh) 2002-12-11
HK1050211B (zh) 2008-01-25
MXPA02003247A (es) 2002-09-30
DE60033679D1 (de) 2007-04-12
NO330916B1 (no) 2011-08-15
HU228933B1 (en) 2013-06-28
BR0014489A (pt) 2002-06-04
CZ20021215A3 (cs) 2002-08-14
EP1224310A1 (de) 2002-07-24
KR20020057969A (ko) 2002-07-12
PL210590B1 (pl) 2012-02-29
FR2799472A1 (fr) 2001-04-13
IL148493A (en) 2010-04-15
BR0014489B1 (pt) 2013-05-21
KR100928105B1 (ko) 2009-11-24
NO20021634D0 (no) 2002-04-05
AU785431B2 (en) 2007-05-31
CA2383225A1 (fr) 2001-04-12
CA2383225C (fr) 2011-12-13
CN1384885B (zh) 2011-06-22
JP5260815B2 (ja) 2013-08-14
CZ302282B6 (cs) 2011-02-02
WO2001025463A1 (fr) 2001-04-12
HK1050211A1 (en) 2003-06-13
JP2003512823A (ja) 2003-04-08
HUP0203801A2 (hu) 2003-03-28
NO20021634L (no) 2002-06-04
FR2799472B1 (fr) 2004-07-16
IL148493A0 (en) 2002-09-12
HUP0203801A3 (en) 2005-01-28
US20090149349A1 (en) 2009-06-11
DK1224310T3 (da) 2007-07-02
PL354099A1 (en) 2003-12-29
AU7794700A (en) 2001-05-10
NZ518763A (en) 2005-01-28
EP1224310B1 (de) 2007-02-28
ZA200202481B (en) 2003-09-23
US8263395B2 (en) 2012-09-11
DE60033679T2 (de) 2007-11-15

Similar Documents

Publication Publication Date Title
ATE310829T1 (de) Zelllinien und konstrukte für die herstellung von e1-deletierten adenoviren in abwesenheit von replikationskompetentem adenovirus
EP1180932A4 (de) Adenovirus mit erhöhter infektiosität und konditionaler replikationsfähigkeit und deren verwendungen
NO962791L (no) Preparater inneholdende nukleinsyrer, deres fremstilling og anvendelse
ATE338821T1 (de) Strukturprotein von aav, seine herstellung und verwendung
ATE291633T1 (de) Rekombinante adenovirale vektoren, die chimäre fiberproteine exprimieren, für die zellspezifische infektion und genomische integration
ATE308621T1 (de) Replizierende retrovirale konstrukte, ihre herstellung und verwendungen für den gentransfer
WO2002024640A3 (en) Recombinant adenovirus vectors that are replication-competent in tert-expressing cells
IL132951A0 (en) Compounds preparation and use for transferring nucleic acids into cells
DE69830251D1 (de) Langes pentraxin ptx3 enthaltende pharmazeutische zusammensetzungen
WO1997026322A3 (en) Methods and compositions for inhibiting hexokinase
EP1070122A4 (de) Induktion apoptischer oder zytotoxischer genexpression durch adenovirus-vermittelten gen-kotransfer
ATE355385T1 (de) Herstellung von rekombinanten adenoviren und von adenovirus-genbanken
DK0843731T3 (da) Adenovirusvektorer til genterapi
MXPA05004074A (es) Nuevos adenovirus, acidos nucleicos que los codifican y su uso.
FR2778670B1 (fr) Methodes et compositions pour la production de particules virales
CA2441535A1 (en) Methods for delivering nucleic acid molecules into cells and assessment thereof
GB2379446A (en) Cells,culture methods and their uses
DE69737597D1 (de) Vektoren zur inhibierung von viralem und tumorwachstum
ATE292675T1 (de) Tetrahydropyrimidin-dioxygenase-gen, dadurch kodierte polypeptide und verfahren zur deren herstellung
MXPA03003983A (es) Formulaciones que comprenden polimeros de dextrina en combinacion con azucares para la administracion de acidos nucleicos.
AU2000265672A1 (en) Somatic cloning gene transfer for the production of recombinant proteins, cells and organs
WO2001098350A3 (en) Compositions comprising net-4 modulations and their use for treating neoplastic disease
Prasad et al. Epithelial cell specific differentiation marker
EP1607483A4 (de) Mit einem virusvektor und einem menschlichen tumorsuppressorgen konstruierte rekombinante und ihre verwendung
AU4216599A (en) Hematopoietic progenitor cell gene transduction

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties